A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Phase of Trial: Phase II
Latest Information Update: 28 Mar 2016
At a glance
- Drugs Olanzapine/samidorphan (Primary) ; Olanzapine
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Alkermes plc
- 28 Mar 2016 Data will be presented at the 5th Biennial Schizophrenia International Research Society (SIRS) Conference 2016, according to an Alkermes plc media release.
- 16 Jun 2015 Results will be presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting 2015, according to an Alkermes media release.
- 06 Apr 2015 Status changed from active, no longer recruiting to completed, according to Alkermes media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History